Aptahem AB Company Description

Aptahem AB (publ), a biotechnology company, engages in the development of ribonucleic acid-based pharmaceuticals in Sweden.

The company’s lead product candidate is Apta-1, which is in Phase I clinical trial for the treatment of patients with sepsis/septic shock and severe inflammatory conditions, as well as to prevent organ and tissue damages in life-threatening conditions.

It also develops Apta-2 which is in preclinical stage for the treatment of inflammation; and Apta-3 which is in discovery stage.

The company has a collaboration with Hongene Biotech for the manufacturing of RNA and oligonucleotides.

Aptahem AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.